Pharmaceuticals

Cancer Immunotherapy Market Outlook 2026–2030 Highlighting Growth Drivers and Trends

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Cancer Immunotherapy Market Between 2026 And 2030?

The cancer immunotherapy market size has shown swift expansion in recent years. It is forecast to increase from $124.09 billion in 2025 to $137.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. This past growth can be ascribed to significant discoveries in tumor immunology, an escalating global incidence of cancer, the initial achievements of monoclonal antibodies, augmented funding for oncology research and development, and regulatory endorsements for checkpoint inhibitors.

The cancer immunotherapy market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $210.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is attributable to factors such as the increasing uptake of CAR T-cell therapies, the broadening scope into solid tumor indications, heightened investment in cancer vaccines, a surge in demand for targeted combination therapies, and favorable reimbursement policies for immunotherapy. Key trends anticipated during the same period encompass the swift adoption of immune checkpoint inhibitors, an escalating reliance on combination immunotherapy regimens, the proliferation of cell-based cancer treatments, an intensified focus on personalized immunotherapy approaches, and a growing volume of oncology clinical trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Key Drivers Are Influencing The Growth Of The Cancer Immunotherapy Market?

The increasing occurrence of cancer is anticipated to drive growth in the cancer immunotherapy market. Global cancer cases are escalating due to factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and various environmental influences. This surge in cancer diagnoses is projected to heighten the demand for cancer immunotherapies, as patients increasingly opt for medical interventions promising improved recovery rates and reduced discomfort. For example, projections from Cancer Research UK, a UK-based cancer charity, indicate that in July 2024, cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases vary, from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a few cancer types are expected to show a decrease, with declines ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising cancer incidence is poised to stimulate the demand for cancer immunotherapy throughout the forecast period.

Which Market Segments Are Examined In The Cancer Immunotherapy Market Study?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Trends Are Influencing The Cancer Immunotherapy Market?

Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to expand access to advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy functions as an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by impeding programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company specializing in oncology and biologics, released HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor approved globally for extensive-stage small cell lung cancer and operates through a dual mechanism targeting PD-L1 and PD-L2, featuring strong receptor internalization to boost immune engagement. Its demonstrated survival benefit and notably reduced cost compared with existing immunotherapies emphasize its clinical worth and broaden patient access to advanced cancer treatment in India.

Who Are The Primary Competitors In The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Read the full cancer immunotherapy market report here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Immunotherapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795